Proteome Sciences plc
(“Proteome Sciences” or the “Company”)

Share Subscription

6th August, 2013. Proteome Sciences is pleased to announce that it received a direct approach from an institutional investor to subscribe for 3,750,000 new ordinary shares of 1p each at a price of 41.5 pence per share. The issue raised approximately £1.57 million which will be used as additional working capital to develop the business.

Application has been made to the London Stock Exchange for the admission of the 3,750,000 new ordinary shares to be admitted to trading on AIM. It is expected that admission will occur and dealings will commence at 08:00 on 12 August 2013.

In conformity with rule 5.6.1 of Disclosure and Transparency Rules, the Board of the Company notifies the market of the following:

The total number of ordinary shares of 1p each in Proteome in issue following the admission of the 3,750,000 new ordinary shares will be 196,248,477 with each share carrying the right to one vote. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Proteome Sciences under the FSA’s Disclosure and Transparency Rules.

Christopher Pearce, CEO, commented:

“I am pleased to see that our strong newsflow is being recognised by institutional investors in this way as they increasingly appreciate the central role played by protein biomarkers in all aspects of drug development and early diagnosis and the underlying importance of our IP. This is reflected through our recent announcements, in particular the strategic contract with Thermo Scientific in June and the excellent results presented at the Alzheimer’s International Congress, Boston in July for the progress of our two lead compounds for CK1d in the tau pathway and the compelling performance of our two peptide panels in blood for early diagnosis of mild cognitive impairment (MCI) and Alzheimer’s disease as we actively engage in outlicensing these to the main global players. They provide considerable potential commercial value for our business and revenue. We were delighted to be approached by an institutional investor and to have a supportive shareholder who has also indicated its intention to increase the size of its holding in the market.”

- Ends -
For further information please contact:

**Proteome Sciences plc**  
Christopher Pearce, Chief Executive Officer  
Dr. Ian Pike, Chief Operating Officer  
Tel: +44 (0)1932 865065  
James Malthouse, Finance Director

**Nominated Adviser**  
Cenkos  
Stephen Keys/Camilla Hume  
Tel: +44 (0)20 7397 8900

**Public Relations**  
IKON Associates  
Adrian Shaw  
Tel: +44 (0)1483 271291

**Notes to Editors:**

**About Proteome Sciences**

Proteome Sciences is a global leader in applied proteomics and peptidomics offering high sensitivity, proprietary technologies for protein and peptide biomarker discovery, validation and assay development. Its PS Biomarker Services™ uses isobaric and isotopic Tandem Mass Tag® (TMT®) workflows developed on the latest Orbitrap® Velos and TSQ Vantage mass spectrometers to deliver rapid, robust and reproducible biomarker assay development for customers in the pharmaceutical, diagnostic and biotechnology sectors. Services are provided from its ISO 9001: 2008 accredited facilities in Frankfurt, Germany. By combining Selected Reaction Monitoring (SRM) and TMT® workflows highly multiplexed assays can be developed rapidly and are suitable for screening hundreds of candidate biomarkers in larger validation studies and can be transferred for immunoassay development. The Company’s own research has discovered a large number of novel protein biomarkers in key human diseases and is focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and patented blood biomarkers, including Alzheimer’s disease, stroke, brain damage and lung cancer for diagnostic and treatment applications that are available for license or are already outlicensed. Proteome Sciences, based in Cobham, UK, with facilities in London and Frankfurt, delivers outsourced proteomics services and proprietary biomarkers/biomarker assays to pharmaceutical, biotechnology and diagnostics companies.

Visit: [http://www.proteomics.com](http://www.proteomics.com)